LT2506840T - Hipoksija sukeliančio faktoriaus inhibitorių naudojimas - Google Patents

Hipoksija sukeliančio faktoriaus inhibitorių naudojimas

Info

Publication number
LT2506840T
LT2506840T LTEP10834883.0T LT10834883T LT2506840T LT 2506840 T LT2506840 T LT 2506840T LT 10834883 T LT10834883 T LT 10834883T LT 2506840 T LT2506840 T LT 2506840T
Authority
LT
Lithuania
Prior art keywords
hypoxxicity
factor inhibitors
inhibitors
factor
hypoxxicity factor
Prior art date
Application number
LTEP10834883.0T
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Sami N. Malek
Pan ZENG
Original Assignee
OncoC4, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc. filed Critical OncoC4, Inc.
Publication of LT2506840T publication Critical patent/LT2506840T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP10834883.0T 2009-12-04 2010-06-25 Hipoksija sukeliančio faktoriaus inhibitorių naudojimas LT2506840T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04
PCT/US2010/039910 WO2011068563A1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number Publication Date
LT2506840T true LT2506840T (lt) 2021-06-25

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10834883.0T LT2506840T (lt) 2009-12-04 2010-06-25 Hipoksija sukeliančio faktoriaus inhibitorių naudojimas

Country Status (15)

Country Link
US (7) US9427413B2 (lt)
EP (2) EP3892264A3 (lt)
CN (2) CN102791260A (lt)
CA (1) CA2782527C (lt)
CY (1) CY1125365T1 (lt)
DK (1) DK2506840T3 (lt)
ES (1) ES2864743T3 (lt)
HR (1) HRP20210537T1 (lt)
HU (1) HUE053793T2 (lt)
LT (1) LT2506840T (lt)
PL (1) PL2506840T3 (lt)
PT (1) PT2506840T (lt)
SI (1) SI2506840T1 (lt)
SM (1) SMT202100234T1 (lt)
WO (1) WO2011068563A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782527C (en) 2009-12-04 2019-09-17 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
CN108135941B (zh) * 2015-08-19 2021-07-27 儿研所儿童医学中心 用于治疗移植物抗宿主病的组合物和方法
SG11201803915UA (en) * 2015-11-10 2018-06-28 Childrens Research Institute Childrens National Medical Center Echinomycin formulation, method of making and method of use thereof
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
ES2578728T3 (es) * 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
JP2009545601A (ja) 2006-08-02 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
CA2782527C (en) 2009-12-04 2019-09-17 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors

Also Published As

Publication number Publication date
WO2011068563A1 (en) 2011-06-09
CA2782527C (en) 2019-09-17
DK2506840T3 (da) 2021-04-12
EP3892264A3 (en) 2021-12-08
US20210161991A1 (en) 2021-06-03
US20200147167A1 (en) 2020-05-14
CA2782527A1 (en) 2011-06-09
US9427413B2 (en) 2016-08-30
US20170239315A1 (en) 2017-08-24
US20120264697A1 (en) 2012-10-18
EP3892264A2 (en) 2021-10-13
CN102791260A (zh) 2012-11-21
SMT202100234T1 (it) 2021-05-07
US20180177841A1 (en) 2018-06-28
PL2506840T3 (pl) 2021-10-11
US20170035832A1 (en) 2017-02-09
HUE053793T2 (hu) 2021-07-28
US9877998B2 (en) 2018-01-30
HRP20210537T1 (hr) 2021-05-14
US20190255140A1 (en) 2019-08-22
CY1125365T1 (el) 2024-02-16
SI2506840T1 (sl) 2021-08-31
EP2506840A1 (en) 2012-10-10
US9623070B2 (en) 2017-04-18
EP2506840B1 (en) 2021-01-06
EP2506840A4 (en) 2013-07-03
PT2506840T (pt) 2021-04-27
CN109224064A (zh) 2019-01-18
ES2864743T3 (es) 2021-10-14

Similar Documents

Publication Publication Date Title
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
CY2019026I1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
SMT201500271B (it) Inibitori di neprilisina
SMT201600291B (it) Inibitori di proteasi hcv
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
SMT201500043B (it) Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
EP2299999A4 (en) STAT3 INHIBITORS
IL237582A0 (en) Cdk inhibitors
IL225867B (en) Coelenterazine substrates
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
EP2568812A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
FI20095529A0 (fi) Probioottien uusi käyttö
BR112012005382A2 (pt) inibidores de jak
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
BR112013014148A2 (pt) inibidores de corrosão
EP2413941A4 (en) Renin Inhibitors